These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33693056)

  • 1. Natural History of Systemic Sclerosis-Related Interstitial Lung Disease: How to Identify a Progressive Fibrosing Phenotype.
    Volkmann ER
    J Scleroderma Relat Disord; 2020 Mar; 5(2 Suppl):31-40. PubMed ID: 33693056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
    Khanna D; Tashkin DP; Denton CP; Renzoni EA; Desai SR; Varga J
    Am J Respir Crit Care Med; 2020 Mar; 201(6):650-660. PubMed ID: 31841044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.
    Fischer A; Patel NM; Volkmann ER
    Open Access Rheumatol; 2019; 11():283-307. PubMed ID: 31849543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-Term Lung Function Changes and Predictors of Progressive Systemic Sclerosis-Related Interstitial Lung Disease.
    Kaenmuang P; Navasakulpong A
    Tuberc Respir Dis (Seoul); 2020 Oct; 83(4):312-320. PubMed ID: 32668825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
    Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
    Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox.
    Nagy A; Palmer E; Polivka L; Eszes N; Vincze K; Barczi E; Bohacs A; Tarnoki AD; Tarnoki DL; Nagy G; Kiss E; Maurovich-Horvat P; Müller V
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on Morbidity and Mortality in Systemic Sclerosis-Related Interstitial Lung Disease.
    Volkmann ER; Fischer A
    J Scleroderma Relat Disord; 2021 Feb; 6(1):11-20. PubMed ID: 33693057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of progression in systemic sclerosis patients with interstitial lung disease.
    Distler O; Assassi S; Cottin V; Cutolo M; Danoff SK; Denton CP; Distler JHW; Hoffmann-Vold AM; Johnson SR; Müller Ladner U; Smith V; Volkmann ER; Maher TM
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32079645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease.
    Watanabe S; Kase K; Saeki K; Ohkura N; Murata A; Waseda Y; Takato H; Ichikawa Y; Yasui M; Kasahara K
    Respir Med; 2022 Jan; 191():106689. PubMed ID: 34844174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.
    Vandecasteele E; Melsens K; Vanhaecke A; Blockmans D; Bonroy C; Carton C; Deschepper E; De Keyser F; Houssiau F; Piette Y; Vanthuyne M; Verbeke K; Westhovens R; Wuyts WA; De Langhe E; Brusselle G; Smith V
    Semin Arthritis Rheum; 2021 Oct; 51(5):969-976. PubMed ID: 34403812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic options for systemic sclerosis related interstitial lung diseases.
    Mouthon L; Bérezné A; Guillevin L; Valeyre D
    Respir Med; 2010 Jul; 104 Suppl 1():S59-69. PubMed ID: 20630349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Sarr C; Freiwald M
    BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interstitial lung disease in systemic sclerosis].
    Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
    Rev Mal Respir; 2007 Oct; 24(8):1035-46. PubMed ID: 18033190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Magnusson MO; Freiwald M
    Respir Med; 2021; 180():106369. PubMed ID: 33798871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
    Jung SM; Park KS; Kim KJ
    Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severity and features of frailty in systemic sclerosis-associated interstitial lung disease.
    Guler SA; Kwan JM; Winstone TA; Milne KM; Dunne JV; Wilcox PG; Ryerson CJ
    Respir Med; 2017 Aug; 129():1-7. PubMed ID: 28732817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review.
    Winstone TA; Assayag D; Wilcox PG; Dunne JV; Hague CJ; Leipsic J; Collard HR; Ryerson CJ
    Chest; 2014 Aug; 146(2):422-436. PubMed ID: 24576924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.